Nasal cavity nursing agent as well as preparation method and application thereof

By using the combination of zinc hyaluronate, polyhexamethylene biguanide and PEG-40 hydrogenated castor oil in nasal care agents, a physical barrier is formed, and the problems of single and unstable components of nasal cleaning products are solved, and the nasal cavity is realized Effectively moisturize and protect, and keep the product clear, transparent and anti-corrosion properties.

CN118903240AActive Publication Date: 2024-11-08SHAANXI BIO REGENERATIVE MEDICINE CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411231761.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-04
Publication Date
2024-11-08
Estimated Expiration
2044-09-04

AI Technical Summary

Technical Problem

The existing nasal cleaning products have single ingredients. Using physiological seawater cleaning solution can easily remove nasal mucus, resulting in symptoms such as dry and itchy nasal cavity, nasal congestion, runny nose, etc., and medical polymer materials can easily react with other components, resulting in unstability of the solution.

Method used

Add zinc hyaluronate, polyhexamethylene biguanide and PEG-40 hydrogenated castor oil to aqueous sodium chloride solution to form a physical barrier to relieve nasal congestion, sneeze, runny nose symptoms, and maintain nasal care agents through specific formulas and preparation methods. Clarified and transparent.

Benefits of technology

It realizes excellent moisturizing and mucosal protection function of the nasal cavity, shortens wound healing time, reduces the risk of infection and inflammation, and maintains the stability and anticorrosion performance of nasal care agents.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903240A_ABST
    Figure CN118903240A_ABST
Patent Text Reader

Abstract

The invention relates to a nasal cavity nursing agent as well as a preparation method and application thereof, and relates to the field of medical nursing products. The nasal cavity nursing agent disclosed by the invention is prepared from the following components in parts by weight: 0.09 to 8.5 parts of sodium chloride, 0.01 to 0.2 part of zinc hyaluronate, 0.003 to 0.15 part of polyhexamethylene biguanide, 0.5 to 2.4 parts of PEG-40 hydrogenated castor oil, water and a pH (Potential of Hydrogen) regulator. The prepared nasal cavity nursing agent is clear and transparent, has excellent antibacterial and anti-inflammatory effects, can form an excellent physical barrier in the nasal cavity, and plays excellent roles in moisturizing the nasal cavity and protecting the mucous membrane of the nasal cavity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical care products, and more specifically relates to a nasal care agent and a preparation method and use thereof. Background Art

[0002] Nasal cleaning products are mainly used to clean, rinse and care for the nasal cavity. When used, the solution is sent to the nasal cavity, nasal passages, sinuses and other parts through high-pressure spray to rinse the nasal cavity, which helps to remove allergic particles such as pollen, exhaust gas, dust particles, etc. in the nasal cavity and avoid contact between allergens and the nasal mucosa.

[0003] By analyzing the 24 nasal cleansing products registered in 2024, it is found that the main ingredient of 83.3% of nasal cleansing products is sea salt water, and the remaining nasal cleansing products only add basic auxiliary materials such as citric acid and chloride, and the ingredients are relatively simple. When using the above-mentioned physiological seawater cleaning solution for nasal cleaning, although it can effectively remove foreign matter such as dust in the nasal cavity, the mucus normally secreted by the nasal mucosa is also easily taken away by the flushing solution, which can easily cause symptoms of dry and itchy nose due to mucosal irritation, and then lead to symptoms such as nasal congestion, runny nose, sneezing, etc. cannot be quickly relieved.

[0004] Adding medical polymer materials to nasal cleaning products can improve the moisturizing properties of the products and overcome the above-mentioned problems caused by simply using physiological seawater cleaning solutions; the addition of some active materials can also enrich the efficacy of the products and promote nasal cleaning products to function faster and more efficiently. However, a considerable number of medical polymer materials are prone to react with other ingredients in the product, resulting in unstable phenomena such as turbid precipitation in the solution, which in turn affects the nasal care performance of the product. How to provide a stable and high-performance nasal care product containing medical polymer materials has become an urgent problem to be solved in this field. Summary of the invention

[0005] In view of the above-mentioned defects and problems of the prior art, the present invention develops a nasal care agent and a preparation method and use thereof.

[0006] The first aspect of the present invention provides a nasal care agent, which comprises, by weight, 0.09-8.5 parts of sodium chloride, 0.01-0.2 parts of zinc hyaluronate, 0.003-0.15 parts of polyhexamethylene biguanide, 0.5-2.4 parts of PEG-40 hydrogenated castor oil, water and a pH regulator.

[0007] Optionally, in parts by weight, the zinc hyaluronate is 0.05-0.15 parts, the polyhexamethylene biguanide is 0.005-0.1 parts, and the PEG-40 hydrogenated castor oil is 0.5-1.5 parts.

[0008] Optionally, in parts by weight, the zinc hyaluronate is 0.15 parts, the polyhexamethylene biguanide is 0.005 parts, and the PEG-40 hydrogenated castor oil is 0.5 parts.

[0009] The present application pays attention to adding zinc hyaluronate, polyhexamethylene biguanide and PEG-40 hydrogenated castor oil to sodium chloride aqueous solution, which can form an excellent physical barrier in the nasal cavity, play an excellent role in nasal moisturizing and protecting the nasal mucosa, and can relieve the symptoms of nasal congestion, sneezing and runny nose. Zinc hyaluronate is prepared by ion exchange between zinc ions and sodium ions on the carboxyl group of sodium hyaluronate, and has the efficacy characteristics of both hyaluronic acid and zinc. Studies have shown that zinc hyaluronate is better than sodium hyaluronate in moisturizing and repairing functions. However, researchers have found in actual studies that zinc hyaluronate is easy to produce turbidity with the preservative effect in the product. The inventor unexpectedly found that by the coordination of each substance of the present invention, it is possible to keep the nasal care agent clear and transparent without affecting the entire nasal care agent on the basis of exerting excellent nasal care performance, without affecting the normal use of the nasal care agent. Moreover, the amount of preservative added in the present application is relatively small, and the toxicity is low, which helps to provide a suitable healing environment for the wound in the nasal cavity, thereby shortening the healing time of the wound and effectively reducing the possibility of wound infection and inflammation.

[0010] Optionally, based on weight, 0.005-0.3 parts of tetrahydromethylpyrimidine carboxylic acid are also included.

[0011] By adding tetrahydromethylpyrimidine carboxylic acid, it helps to further balance the extracellular and extracellular osmotic pressure of cells in the nasal cavity, and then by increasing the hydration of the lipid membrane surface, increasing the lipid membrane flow dynamics, and improving the cell membrane's ability to withstand extreme environmental pressure, it effectively promotes the skin in the nasal cavity from being damaged.

[0012] Optionally, a functional component is further included. Preferably, the functional component includes a flavoring agent; more preferably, the flavoring agent is menthol.

[0013] Optionally, the pH adjuster is sodium dihydrogen phosphate and disodium hydrogen phosphate; preferably, the pH of the nasal care agent is 5-6.

[0014] Another aspect of the present invention also provides a method for preparing the above-mentioned nasal cavity care agent, comprising the following steps:

[0015] (1) mixing a sodium chloride aqueous solution and zinc hyaluronate at a temperature of 50 to 90° C. and keeping the mixture warm for 10 to 30 minutes to obtain a first solution;

[0016] (2) adding PEG-40 hydrogenated castor oil to the first solution and keeping the temperature for 10 to 30 minutes to obtain a second solution;

[0017] (3) The second solution is cooled to 20-30° C., polyhexamethylene biguanide is added, and the mixture is stirred to obtain a third solution.

[0018] (4) Adding a pH adjuster to the third solution to adjust the pH of the third solution to 5-6, stirring and discharging the solution to obtain a nasal care agent.

[0019] Optionally, step (2) further comprises cooling the second solution to 40-60° C. and then adding tetrahydromethylpyrimidine carboxylic acid.

[0020] Optionally, step (2) further comprises mixing a functional component with the PEG-40 hydrogenated castor oil and then adding the mixture to the second solution; preferably, the functional component comprises a flavoring agent; more preferably, the flavoring agent is menthol.

[0021] In a third aspect, the present application also provides the use of the above-mentioned nasal care agent for preparing a product for treating or alleviating nasal discomfort symptoms; preferably, the nasal discomfort symptoms include nasal congestion, runny nose and / or sneezing.

[0022] In summary, this application has the following beneficial effects:

[0023] Adding zinc hyaluronate, polyhexamethylene biguanide, pH regulator and PEG-40 hydrogenated castor oil to the sodium chloride aqueous solution can form an excellent physical barrier in the nasal cavity, play an excellent role in nasal moisturizing and protecting the nasal mucosa, shorten the healing time of wounds, and effectively reduce the possibility of infection and inflammation of wounds in the nasal cavity. The various substances cooperate with each other, and on the basis of not affecting the excellent nursing performance of the entire nasal care agent, the nasal care agent can always remain clear and transparent, and promote the full play of each component. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art are briefly introduced below.

[0025] Figure 1 It is the apparent state diagram of Example 1, Example 3, Example 4 and deionized water;

[0026] Figure 2 The following are the microscopic examination results of the sample mucosal tissue sections prepared in Example 4 and the mucosal tissue sections of the control group. DETAILED DESCRIPTION

[0027] The present application is further described in detail with reference to the following examples. It should be noted that if no specific conditions are specified in the following examples, the conventional conditions or the conditions recommended by the manufacturer are followed, and the raw materials used in the following examples can be obtained from common commercial sources unless otherwise specified.

[0028] In order to make the above-mentioned purposes, features and advantages of the present application more obvious and easy to understand, the specific implementation methods of the present application are described in detail below. In the following description, many specific details are set forth to facilitate a full understanding of the present application. However, the present application can be implemented in many other ways different from those described herein, and those skilled in the art can make similar improvements without violating the connotation of the present application, so the present application is not limited by the specific embodiments disclosed below.

[0029] In this application, "first aspect", "second aspect", "third aspect", etc. are used only for descriptive purposes and cannot be understood as indicating or implying relative importance or quantity, nor can they be understood as implicitly indicating the importance or quantity of the indicated technical features. Moreover, "first", "second", "third", etc. only serve the purpose of non-exhaustive enumeration and description, and it should be understood that they do not constitute a closed limitation on quantity.

[0030] In this application, "preferably", "optional", and "optional" mean optional, that is, any one of the two parallel schemes of "yes" or "no". If multiple "options" appear in a technical solution, unless otherwise specified and there is no contradiction or mutual restriction, each "optional" is independent.

[0031] In this application, when it comes to numerical ranges, unless otherwise specified, the above numerical ranges are deemed to be continuous and include the minimum and maximum values ​​of the range, as well as each value between such minimum and maximum values. Further, when a range refers to an integer, each integer between the minimum and maximum values ​​of the range is included. In addition, when multiple ranges are provided to describe features or characteristics, the ranges can be merged. In other words, unless otherwise specified, all ranges disclosed herein should be understood to include any and all subranges included therein.

[0032] In the present application, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.

[0033] Unless otherwise defined, all technical and scientific terms used in this application have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used in this application and in the specification of this application are only for the purpose of describing specific embodiments and are not intended to limit this application.

[0034] First, the sources of the main raw materials in the present invention are described:

[0035] HA-Zn, purchased from Shandong Zhongshan Biotechnology Co., Ltd., molecular weight: 5kDa-2000kDa.

[0036] PEG-40 hydrogenated castor oil, purchased from BASF, CAS number is 61788-85-0.

[0037] Examples 1-5

[0038] The preparation method of the nasal care agent in Examples 1-5 is as follows:

[0039] (1) Add 30 g of a 0.9% sodium chloride aqueous solution into a container, add 0.15 g of hyaluronate zinc (HA-Zn) at 80° C., and keep the temperature for 15 minutes under stirring to obtain a first solution.

[0040] (2) PEG-40 hydrogenated castor oil and 0.01 g of menthol were mixed and added to the first solution, and the mixture was kept warm for 20 minutes to obtain a second solution; when the second solution was cooled to 40° C., 0.05 g of tetrahydromethylpyrimidine carboxylic acid was added to the second solution.

[0041] (3) The second solution is further cooled to 25° C., a preservative is added, and the mixture is stirred to obtain a third solution;

[0042] (4) adding sodium dihydrogen phosphate and disodium hydrogen phosphate to the third solution, adjusting the pH of the third solution to 6, stirring for 8 minutes, and then discharging the solution to obtain a nasal care agent.

[0043] In Examples 1-5, the type and addition amount of each substance are shown in Table 1. It should be noted that when the antiseptic effect and the human trial results are both satisfied, the minimum addition amount of benzalkonium chloride is 0.01 g, so Example 1 of the present application uses 0.01 g of benzalkonium chloride.

[0044] Table 1. Type and amount of each substance in Examples 1-5

[0045]

[0046]

[0047] Embodiment 6-14

[0048] (1) adding 30 g of a 0.9% sodium chloride aqueous solution into a container, adding HA-Zn at a temperature of 80° C., and keeping the temperature for 15 minutes under stirring to obtain a first solution;

[0049] (2) PEG-40 hydrogenated castor oil and 0.01 g of menthol were added to the first solution and kept warm for 20 minutes to obtain a second solution; when the second solution was cooled to 40° C., 0.05 g of tetrahydromethylpyrimidine carboxylic acid was added to the second solution.

[0050] (3) cooling the second solution to 25° C., adding polyhexamethylene biguanide, and stirring to obtain a third solution;

[0051] (4) adding sodium dihydrogen phosphate and disodium hydrogen phosphate to the second solution, adjusting the pH of the third solution to 6, stirring for 8 minutes, and then discharging the solution to obtain a nasal care agent.

[0052] Among them, the amount of HA-Zn (represented by "A"), the amount of PEG-40 hydrogenated castor oil (represented by "B") and the amount of polyhexamethylene biguanide (represented by "C") were used as the three factors to be investigated, and each factor had three levels. 4 Orthogonal array arrangement experiment (L3 4 The orthogonal table can be found in Table 3). Nine experiments are required, and the orthogonal experimental factor level table is shown in Table 2.

[0053] Table 2. Orthogonal experimental factor level table

[0054]

[0055] Embodiment 15

[0056] The preparation method of the nasal care agent is as follows:

[0057] The difference from Example 4 is that menthol and ectoine are not added in step (2).

[0058] Detection experiment

[0059] Test Example 1: Clarity Test

[0060] (1) Observation of apparent state

[0061] The transparency of the samples obtained in Examples 1-5 was observed by naked eye, and a deionized water solution was used as a control group. The results are shown in Figure 1 It should be noted that, for the convenience of observation, 120 mL of samples and deionized water in Examples 1-5 were taken and left to stand for naked eye observation. Among them, the apparent states of the samples prepared in Examples 2 and 3 are similar, and the apparent states of the samples prepared in Examples 5 and 4 are similar.

[0062] Depend on Figure 1It can be clearly known that when the preservative in the present application is benzalkonium chloride, although the antiseptic performance can reach the standard, the turbidity of the obtained nasal care agent sample is high, which is not conducive to normal use (Example 1); and when the preservative is selected as 0.005-0.01g polyhexamethylene biguanide, the turbidity of the sample can be greatly reduced (Example 2 and Example 3). On this basis, the present invention creatively proposes to add 0.5g PEG-40 hydrogenated castor oil. At this time, the clarity of the obtained nasal care agent sample is better (the clarity of the nasal care agent samples obtained by naked eye observation of Example 4 and Example 5 is consistent with the clarity of deionized water). This may be that polyhexamethylene biguanide can cooperate with PEG-40 hydrogenated castor oil to play a synergistic role and promote the clarity and transparency of the nasal care agent. In addition, the researchers found during the experiment that after adding 1g PEG-40 hydrogenated castor oil to the sample in Example 1, the clarity of the sample did not change significantly, and the apparent state was basically similar to Example 1. It can be seen that not all preservatives can produce a synergistic effect with PEG-40 hydrogenated castor oil.

[0063] (2) Sample transmittance test

[0064] In order to further verify the specific effects of different formulas on the clarity of the nasal care agent, a 0.5 turbidity standard solution was prepared according to the first method of the clarity test method of 0902 in the 2020 edition of the Chinese Pharmacopoeia, and the transmittance (T%) at a wavelength of 550nm was used as an indicator to measure the transmittance of the 0.5 turbidity standard solution and the samples prepared in Examples 6 to 14. The clarity of each sample was determined by comparing the transmittance, and the optimal formula of the nasal care agent was obtained. The orthogonal experimental table of Examples 6 to 14 is shown in Table 3.

[0065] It should be noted that in Table 3, the K value represents the sum of the indicators at each level of each factor. Specifically, K1 in a column represents the mean of the sum of the numerical values ​​of the test indicators corresponding to the "1" level in the column, K2 in a column represents the mean of the sum of the numerical values ​​of the test indicators corresponding to the "2" level in the column, and so on. The formula composed of the factors and levels corresponding to the maximum K value in each column is the best formula. The R value of each column represents the difference between the maximum and minimum values ​​of the K value in the column. The larger the R value of a factor, the greater the influence of the corresponding test indicator factor in the column on the experimental results.

[0066] Table 3. Orthogonal experiment table

[0067]

[0068]

[0069] As can be seen from Table 3, the combination of PEG-40 hydrogenated castor oil, polyhexamethylene biguanide, and zinc hyaluronate can keep the nasal care agent clear and promote the full effect of each substance. The order of priority of the factors affecting transmittance is C>A>B, that is, the amount of polyhexamethylene biguanide>the amount of HA-Zn>the amount of PEG-40 hydrogenated castor oil. It is worth noting that the best formula of this scheme is A3B1C1, that is, when the addition amount of HA-Zn is 0.15g, the addition amount of PEG-40 hydrogenated castor oil is 0.5g, and the addition amount of polyhexamethylene biguanide is 0.005g, the clarity of the obtained nasal care agent is higher. At this time, the transmittance (T%) of the nasal care agent at a wavelength of 550nm is 92.7%.

[0070] Test Example 2: Anti-corrosion Performance Test

[0071] In order to further clarify whether the presence of PEG-40 hydrogenated castor oil affects the antiseptic performance of the entire nasal care agent, the present invention is also based on the 2020 edition of the "Chinese Pharmacopoeia" 1121 antibacterial efficacy test method, and refers to Table 2-2 (nasal preparations, ear preparations, skin preparations, inhalation preparations antibacterial efficacy judgment standards) in the antibacterial efficacy test method to determine the antibacterial activity of samples obtained in Examples 3-5 and related reference examples. The single bacteria inoculation method was adopted, and the entire test period was 28 days. Sampling was measured on the 0th day, 2nd day, 7th day, 14th day and 28th day after inoculation, and the results are shown in Table 4.

[0072] The difference between the operation method of the relevant control example in Table 4 and that of Example 4 is that no polyhexamethylene biguanide is added, and the addition amount of PEG-40 hydrogenated castor oil is 0.505 g.

[0073] Table 4. Anticorrosion performance test data of samples prepared from Examples 1-4 and related control examples

[0074]

[0075]

[0076] According to the data in Table 4, 0.005 g of polyhexamethylene biguanide can make the entire nasal care agent achieve better antiseptic performance (see the data in Example 3). After adding PEG-40 hydrogenated castor oil, the antiseptic performance of polyhexamethylene biguanide can be further improved on the basis of achieving better clarity of nasal care (see the data in Examples 4 and 5). However, from the data in the relevant control examples, it can be seen that PEG-40 hydrogenated castor oil itself does not make the system achieve the effect of antiseptic performance, which shows that the addition of PEG-40 hydrogenated castor oil has no inhibitory effect on the antiseptic effect of the preservative, but has a synergistic effect with the preservative. This may be because after the addition of PEG-40 hydrogenated castor oil, it interacts with the molecules of various substances in the entire nasal care agent, which helps to greatly improve the antiseptic effect.

[0077] It should be noted that although the synergistic effect of PEG-40 hydrogenated castor oil on the preservative efficacy is greater when the addition amount is 1g than when it is 0.5g, when the product performance meets the standard, the minimum addition amount of the material is generally taken as the appropriate addition amount. It should also be noted that when achieving the same preservative performance, the addition amount of polyhexamethylene biguanide can be significantly lower than that of other preservatives, which helps to reduce the possibility of the final nasal care agent irritating the nasal cavity.

[0078] Test Example 3: Performance test of nasal care agent

[0079] (1) Effectiveness test

[0080] The nasal care agent samples prepared in the above-mentioned Examples 4 and 15 were filled in pressure tanks with the same set pressure and applied to 120 volunteers with nasal discomfort (such as patients with rhinitis), of which 60 were given the nasal care agent samples prepared in Example 4 and 60 were given the nasal care agent samples prepared in Example 15. The nasal care agent was treated for 5 days, 6 times / day. During each spraying, the nozzle was pressed to allow the nasal care agent sample to be sprayed into the nasal cavity until it naturally flowed out and then stopped pressing. Observation was performed on the 6th day. Statistical methods: The data were statistically processed using SPSS24.0 statistical software.

[0081] Observation index: Record the disappearance time of nasal congestion, runny nose, sneezing and adverse reactions in the test group and the control group. The specific symptom judgment criteria are as follows: cured: nasal congestion, sneezing and runny nose symptoms disappear within 48 hours; marked effect: nasal congestion, sneezing and runny nose symptoms are alleviated within 72 hours; effective: nasal congestion and runny nose symptoms are not significantly alleviated; ineffective, not reaching the above standards. Total effective rate = (number of cured cases + number of markedly effective cases) / total number of cases × 100%. The results of Example 4 and Example 15 are shown in Table 5:

[0082] Table 5. Effectiveness data of nasal care agents prepared in Example 4 and Example 15

[0083] Group Total number of cases get well Significant effect efficient invalid Total Effectiveness p-value Example 4 60 30 28 1 1 97% 0.356 Embodiment 15 60 28 29 3 0 95% 0.339

[0084] Experimental studies have shown that after 5 days of treatment, the nasal care agent prepared in this application can effectively relieve the symptoms of nasal congestion, runny nose and sneezing. Since the synergistic effect between zinc hyaluronate, polyhexamethylene biguanide and PEG-40 hydrogenated castor oil is effectively utilized, each substance can play its role to the maximum extent, and the prepared nasal care agent has good clarity and excellent antiseptic properties, filling the gap in the application of zinc hyaluronate in nasal care agents.

[0085] (2) Safety Testing

[0086] The inside and outside of the golden hamster's oral cavity were cleaned and disinfected with iodine tincture, and a cotton ball soaked with the nasal care agent prepared in Example 4 was placed in a cheek pouch on one side of the golden hamster's oral cavity as the experimental group. A control group cotton ball soaked with saline was placed in the other cheek pouch for acute contact. After each contact with the cheek pouch for 10 minutes, the cotton ball was removed, and the cheek pouch was rinsed with saline to check for abnormalities. Care should be taken not to contaminate the other cheek pouch. The above steps were repeated once every hour for a total of 4 hours. The mucosal tissues of the experimental group and the control group were stained with HE and examined under a microscope (the results of the microscopy are shown in Table 1). Figure 2 ), and carry out the following evaluations in turn:

[0087] (1) Visual observation and evaluation

[0088] After removing the cotton ball, the cheek pouch was visually observed and the cheek pouch was checked before each contact (if repeated contact was required). The general condition of the animal was described and the score of the erythema reaction on the cheek pouch surface of the animal during each observation period was determined according to the scoring system given in Table 6. The scoring results are shown in Table 7.

[0089] Table 6. Scoring system for buccal pouch erythema reaction

[0090] reaction Scoring (points) No erythema 0 Very slight erythema (barely visible) 1 Mild erythema (clearly visible) 2 Moderate erythema 3 Severe erythema (purple red) to eschar formation that interferes with grading of erythema 4

[0091] Table 7. Drug administration site scoring table

[0092]

[0093] (2) According to the oral mucosal tissue reaction microscopy scoring system (see Table 8) and the irritation index scoring system (see Table 9), the animal tissue reaction score and irritation index were calculated. The specific scoring results are shown in Table 10.

[0094] Table 8. Microscopic scoring system for oral mucosal tissue reactions

[0095]

[0096] Table 9. Irritation Index Scoring System

[0097] Average score (points) Degree of reaction 0 No stimulation 1~4 Very mild stimulation 5~8 Mild irritation 9~11 Moderate stimulation 12~16 Severe stimulation

[0098] Table 10. Scoring of histopathological examination results of oral mucosal irritation reaction

[0099]

[0100]

[0101] According to the data in Table 7 and Table 10 and Figure 2 The test results show that the nasal care agent prepared by the present invention is safe and non-irritating, and is applicable to a wide range of groups.

[0102] Summary: The present invention is concerned that the nasal cleaning products currently on the market are mainly based on physiological seawater cleaning solutions, which are prone to cause nasal discomfort, and aims to provide a nasal care agent containing zinc hyaluronate with good care effect and high safety. However, the nasal care agent containing zinc hyaluronate and preservatives at the same time is prone to turbidity. The present invention unexpectedly discovered that adding zinc hyaluronate, polyhexamethylene biguanide, pH regulator and PEG-40 hydrogenated castor oil to sodium chloride can form an excellent physical barrier in the nasal cavity, play an excellent role in nasal moisturizing and protecting the nasal mucosa, and the various substances cooperate with each other, which can keep the nasal care agent clear and transparent without affecting the excellent care performance of the entire nasal care agent, so that each component can fully play its role.

[0103] It should be understood that the disclosed invention is not limited only to the specific method, scheme and material of description, because these all can change.It should also be understood that the terminology used herein is only for the purpose of describing specific embodiment scheme, rather than being intended to limit the scope of the present invention, and the scope of the present invention is only limited to the appended claims.

[0104] Those skilled in the art will also recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are also intended to be encompassed by the appended claims.

Claims

1. A nasal care agent, characterized in that: By weight, the invention comprises 0.09-8.5 parts of sodium chloride, 0.01-0.2 parts of zinc hyaluronate, 0.003-0.15 parts of polyhexamethylene biguanide, 0.5-2.4 parts of PEG-40 hydrogenated castor oil, water and a pH regulator.

2. The nasal care agent according to claim 1, characterized in that In terms of weight, the zinc hyaluronate is 0.05-0.15 parts, the polyhexamethylene biguanide is 0.005-0.1 parts, and the PEG-40 hydrogenated castor oil is 0.5-1.5 parts.

3. The nasal care agent according to claim 2, characterized in that: In terms of weight, the zinc hyaluronate is 0.15 parts, the polyhexamethylene biguanide is 0.005 parts, and the PEG-40 hydrogenated castor oil is 0.5 parts.

4. The nasal care agent according to claim 1, characterized in that: By weight, 0.005-0.3 parts of tetrahydromethylpyrimidine carboxylic acid are also included.

5. The nasal care agent according to claim 1, characterized in that: The invention also comprises a functional component, preferably, the functional component comprises a flavoring agent; more preferably, the flavoring agent is menthol.

6. The nasal care agent according to claim 1, characterized in that: The pH regulator is sodium dihydrogen phosphate and disodium hydrogen phosphate; preferably, the pH of the nasal care agent is 5-6.

7. The method for preparing the nasal care agent according to any one of claims 1 to 6, characterized in that: The steps include: (1) mixing sodium chloride, water and zinc hyaluronate at a temperature of 50 to 90° C. and keeping the mixture warm for 10 to 30 minutes to obtain a first solution; (2) adding PEG-40 hydrogenated castor oil to the first solution and keeping the temperature for 10 to 30 minutes to obtain a second solution; (3) cooling the second solution to 20-30° C., adding polyhexamethylene biguanide, and stirring to obtain a third solution; (4) Adding a pH adjuster to the third solution to adjust the pH of the third solution to 5-6, stirring and discharging the solution to obtain a nasal care agent.

8. The preparation method according to claim 7, characterized in that: Step (2) further comprises cooling the second solution to 40-60° C. and then adding tetrahydromethylpyrimidine carboxylic acid.

9. The preparation method according to claim 7, characterized in that: Step (2) further comprises mixing a functional component with the PEG-40 hydrogenated castor oil and then adding the mixture to the second solution; preferably, the functional component comprises a flavoring agent; more preferably, the flavoring agent is menthol.

10. Use of the nasal care agent according to any one of claims 1 to 6 for preparing a product for treating or alleviating nasal discomfort symptoms; preferably, the nasal discomfort symptoms include nasal congestion, runny nose and / or sneezing.

Citation Information

Patent Citations

  • Nasal cavity air particle blocking agent, production method and application thereof

    CN103432159A

  • Nasal spray product for treating or preventing cold and application thereof

    CN106361699A

  • Composition for nasal cavity

    CN111603478A

  • Self-preserving composition

    US20070297990A1